NM_000138.5:c.2547C>G
Variant summary
Our verdict is Uncertain significance. The variant received 0 ACMG points: 3P and 3B. PM1PP2BP4_ModerateBP6
The NM_000138.5(FBN1):c.2547C>G(p.Ile849Met) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000595 in 1,613,968 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/19 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. I849V) has been classified as Uncertain significance.
Frequency
Consequence
NM_000138.5 missense
Scores
Clinical Significance
Conservation
Publications
- familial thoracic aortic aneurysm and aortic dissectionInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet
- Marfan syndromeInheritance: AD, AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, ClinGen, G2P, PanelApp Australia, Orphanet, Ambry Genetics
- Acromicric dysplasiaInheritance: AD Classification: STRONG, SUPPORTIVE Submitted by: Orphanet, Ambry Genetics
- progeroid and marfanoid aspect-lipodystrophy syndromeInheritance: AD Classification: STRONG, MODERATE, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, Orphanet
- stiff skin syndromeInheritance: AD Classification: STRONG, LIMITED Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae)
- Weill-Marchesani syndrome 2, dominantInheritance: AD Classification: STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae)
- geleophysic dysplasiaInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- isolated ectopia lentisInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- neonatal Marfan syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Weill-Marchesani syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- ectopia lentis 1, isolated, autosomal dominantInheritance: AD Classification: LIMITED Submitted by: G2P
- Shprintzen-Goldberg syndromeInheritance: AD, Unknown Classification: LIMITED, NO_KNOWN Submitted by: ClinGen, Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 0 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152186Hom.: 0 Cov.: 33 show subpopulations
GnomAD2 exomes AF: 0.0000358 AC: 9AN: 251344 AF XY: 0.0000368 show subpopulations
GnomAD4 exome AF: 0.0000629 AC: 92AN: 1461782Hom.: 0 Cov.: 32 AF XY: 0.0000578 AC XY: 42AN XY: 727202 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152186Hom.: 0 Cov.: 33 AF XY: 0.0000269 AC XY: 2AN XY: 74342 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Marfan syndrome Uncertain:3Benign:1
PP4 -
- -
The p.Ile849Met variant in the FBN1 gene has been previously reported in 1 individual with Marfan syndrome. This individual also had a co-occurring likely pathogenic variant in FBN1 (p.Gly1838Cys) (Proost et al., 2015; Groth et al., 2017; Meester et al., 2022). This variant has been identified in 4/34590 Latino/Admixed American chromosomes (9/251344 chromosomes overall) by the Genome Aggregation Database (http://gnomad.broadinstitute.org/). This allele frequency is higher than expected for a pathogenic variant. This variant is present in ClinVar (Variation ID: 406321). The FBN1 gene has fewer missense variants in the general population than expected. A low rate of missense variation may suggest that this gene is intolerant to missense variation. Computational tools predict that this variant is neither deleterious nor benign; however, the accuracy of in silico algorithms is limited. These data were assessed using the ACMG/AMP variant interpretation guidelines. In summary, the significance of the p.Ile849Met variant is uncertain. Additional information is needed to resolve the significance of this variant. [ACMG evidence codes used: BS1; PP2] -
This missense variant replaces isoleucine with methionine at codon 849 of the FBN1 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with Marfan syndrome; this individual also carried a different likely pathogenic missense variant in the same gene (PMID: 25907466). This variant has been identified in 9/251344 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Familial thoracic aortic aneurysm and aortic dissection Uncertain:2Benign:1
The p.I849M variant (also known as c.2547C>G), located in coding exon 21 of the FBN1 gene, results from a C to G substitution at nucleotide position 2547. The isoleucine at codon 849 is replaced by methionine, an amino acid with highly similar properties. This variant was reported in one individual from a Marfan syndrome cohort; however, an additional FBN1 variant was also detected, and clinical information was not provided (Proost D et al. Hum. Mutat., 2015 Aug;36:808-14). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. -
- -
- -
not provided Uncertain:1
Identified in a patient with bicuspid aortic valve and TAAD phenotype in published literature (Proost et al., 2015); this patient also harbored a second variant in the FBN1 gene; Does not affect a cysteine residue within a calcium-binding EGF-like domain or a TGF-binding protein domain of the FBN1 gene; cysteine substitutions in the calcium-binding EGF-like domains represent the majority of pathogenic missense changes associated with FBN1-related disorders (Collod-Beroud et al., 2003); In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 27906200, 12938084, 25907466) -
FBN1-related disorder Uncertain:1
The FBN1 c.2547C>G variant is predicted to result in the amino acid substitution p.Ile849Met. This variant has been reported, along with another missense variant p.Gly1838Cys in FBN1, in one individual with Marfan syndrome (Table S2, Proost et al. 2015. PubMed ID: 25907466). This variant is reported in 0.012% of alleles in individuals of Latino descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -
not specified Benign:1
Variant summary: FBN1 c.2547C>G (p.Ile849Met) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 3.6e-05 in 251344 control chromosomes, predominantly at a frequency of 0.00012 within the Latino subpopulation in the gnomAD database. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.2547C>G has been reported in the literature in an individual affected with Marfan Syndrome, however this patient also carried a likely pathogenic FBN1 variant (Proost_2015), suggesting that our variant of interest is in the benign spectrum. In addition, a co-occurrence with another likely pathogenic variant has been reported (FBN1 c.6871+1G>T; in an internal LCA sample), providing further evidence in support of a benign role. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. A recent study combining ACMG criteria with FBN1 gene-specific knowledge (i.e. considering critical FBN1 regions and appropriate minor allele frequency cutoffs), classified the variant as likely benign (Baudhuin_2019).To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 31227806, 27906200, 25907466). ClinVar contains an entry for this variant (Variation ID: 406321). Based on the evidence outlined above, the variant was classified as likely benign. -
Marfan syndrome;C4707243:Familial thoracic aortic aneurysm and aortic dissection Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at